CN103142641B - Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof - Google Patents
Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof Download PDFInfo
- Publication number
- CN103142641B CN103142641B CN201310076599.2A CN201310076599A CN103142641B CN 103142641 B CN103142641 B CN 103142641B CN 201310076599 A CN201310076599 A CN 201310076599A CN 103142641 B CN103142641 B CN 103142641B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- calcium carbonate
- preparation
- calcium
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011712 vitamin K Substances 0.000 title claims abstract description 42
- 229940046010 vitamin k Drugs 0.000 title claims abstract description 42
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000011575 calcium Substances 0.000 title claims abstract description 38
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 62
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 32
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 32
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 31
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 27
- 239000000080 wetting agent Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- -1 ethanol vitamin K Chemical class 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- QIWDGSYHBCMXSI-UHFFFAOYSA-J tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CC=CC2=C(OP([O-])([O-])=O)C(C)=CC(OP([O-])([O-])=O)=C21 QIWDGSYHBCMXSI-UHFFFAOYSA-J 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 12
- 229930006000 Sucrose Natural products 0.000 abstract description 12
- 239000005720 sucrose Substances 0.000 abstract description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract description 8
- 239000011734 sodium Substances 0.000 abstract description 8
- 229910052708 sodium Inorganic materials 0.000 abstract description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 6
- 229930195725 Mannitol Natural products 0.000 abstract description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000008101 lactose Substances 0.000 abstract description 6
- 239000000594 mannitol Substances 0.000 abstract description 6
- 235000010355 mannitol Nutrition 0.000 abstract description 6
- 239000000741 silica gel Substances 0.000 abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 229920002472 Starch Polymers 0.000 abstract description 4
- 239000008107 starch Substances 0.000 abstract description 4
- 235000019698 starch Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 11
- 230000037182 bone density Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000011772 phylloquinone Substances 0.000 description 6
- 239000007910 chewable tablet Substances 0.000 description 5
- 229940068682 chewable tablet Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical group C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 2
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical group C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a calcium carbonate-vitamin K pharmaceutical preparation and a preparation method thereof, belonging to the technical field of medicine. The calcium carbonate-vitamin K pharmaceutical preparation is prepared from 800-2800 parts by weight of calcium carbonate, 2-30 parts by weight of vitamin K and a right amount of auxiliary material, wherein the auxiliary material is selected from one or more of sucrose, microcrystalline cellulose, sodium carboxymethyl starch, micropowder silica gel, magnesium stearate, hydroxypropyl methylcellulose, talcum powder, lactose and mannitol. By using the scientific formula, the calcium carbonate-vitamin K pharmaceutical preparation can effectively supplement calcium, and is safe and convenient to take.
Description
Technical field
The present invention relates to medical art, be specifically related to a kind of calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof.
Background technology
Calcium is a kind of inorganic salt that people's in-vivo content is maximum, in normal human, the content of calcium accounts for the 0.5%-2.0% of human body weight, wherein the calcium of 99% is present among skeleton and tooth, the calcium great majority of 1% are present in soft tissue, extracellular fluid and blood in ionic condition, remain dynamic equilibrium with skeleton.Calcium has the normal reaction maintaining nerve, muscle, regulates heartbeat to keep heart alternately to shrink continuously and diastole, maintains the contraction of muscle and neururgic transmission isoreactivity.China resident, due to dietary habit problem, totally needs generally to carry out suitable replenishing the calcium, could ensure that resident is healthy better.Solve the problem of replenishing the calcium now, the general absorption rate adopting intake and the raising calcium increasing calcium.At present, calcium supplementing product is more, and the formula too complex wherein had also relates to supplementary various nutrient elements, and effect of supplemented calcium is not obvious; Some calcium supplementing product doses are too large, and are not easily absorbed by the body, and cause effect of supplemented calcium poor; Some calcium supplementing products also also exist the problems such as side effect is large.Therefore, it is obvious how developmental research goes out a kind of effect of supplemented calcium, and the calcium supplementing product taking safe ready becomes a technical problem being badly in need of solving.
Summary of the invention
The object of this invention is to provide a kind of calcium carbonate-vitamin K pharmaceutical preparation that a kind of effect of supplemented calcium is obvious, take safe ready.
Another object of the present invention is to provide a kind of preparation method of calcium carbonate-vitamin K pharmaceutical preparation.
The technical solution used in the present invention is a kind of calcium carbonate-vitamin K pharmaceutical preparation, it is made up of 800 ~ 2800 weight parts of calcium carbonate, 2 ~ 30 part by weight of vitamin K and appropriate amount of auxiliary materials, and wherein adjuvant to be selected from sucrose, microcrystalline Cellulose, carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, hypromellose, Pulvis Talci, lactose or mannitol one or more.
As preferably, the present invention is made up of 1000 ~ 2500 weight parts of calcium carbonate, 5 ~ 25 part by weight of vitamin K and appropriate amount of auxiliary materials, and wherein adjuvant to be selected from sucrose, microcrystalline Cellulose, carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, hypromellose, Pulvis Talci, lactose or mannitol one or more.
As preferably, the present invention is made up of 1200 ~ 2000 weight parts of calcium carbonate, 10 ~ 20 part by weight of vitamin K and appropriate amount of auxiliary materials, and wherein adjuvant to be selected from sucrose, microcrystalline Cellulose, carboxymethyl starch sodium, micropowder silica gel, magnesium stearate, hypromellose, Pulvis Talci, lactose or mannitol one or more.As preferably, described pharmaceutical preparation is tablet, capsule or granule.
As preferably, described tablet is conventional tablet, Film coated tablets or chewable tablet.
As preferably, described vitamin K is selected from vitamin K
1, vitamin K
2, vitamin K
3or vitamin K
4in one and any mixture.
Pharmaceutical preparation of the present invention can adopt customary preparation methods to prepare.And above-mentioned each raw material is made the preferred preparation method of pharmaceutical preparation of the present invention comprise the following steps: get calcium carbonate 1600g, vitamin K
36g, vitamin K
4then 6g is the dissolve with ethanol vitamin K of 95% by 30ml concentration
3, vitamin K
4, then add the dilution of 200ml purified water, obtain wetting agent for subsequent use.By calcium carbonate gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, add magnesium stearate 3g mixing, use Capsules filling, to obtain final product.
Beneficial effect of the present invention is: (1) scientific formulation of the present invention is reasonable, and calcium carbonate provides calcium source for body; Vitamin K can regulate the deposition of calcium in bone matrix, can promote the reconstruction of bone and the mobilization of calcium.Both are used in conjunction with each other, and body can be made to absorb calcium carbonate more abundant, and effectively can deposit on skeleton, thus effectively increase bone density, reduce risk of bone fracture.(2) the present invention due to formula reasonable, in order to be effective while the consumption of reduction calcium source, thus the many discomforts because long-term, high-dose uses series products of replenishing the calcium to cause can be avoided, such as gastric mucosa damage, Calculus of digestive duct and urinary tract infringement etc.(3) the present invention is by short-period used, effectively can treat the osteoporosis because calcium deficiency causes and rickets, through routine clinical verification up to a hundred, safe and reliable, has no side effect.(4) the present invention is by adding appropriate adjuvant, meets preparation needs, thus can more meet sufferer demand.
For confirming effectiveness of the present invention, spy evaluates according to Ministry of Public Health " health food inspection and assessment technical specification ", and evaluation result is in table 1.
Experimental technique: get the SPF level female sd inbred rats 60 that body weight is 220-260g, with normal feedstuff adaptability feed after seven days, according to body weight, be divided into following six groups at random: three dosage groups of sham operated rats, model control group, the embodiment of the present invention eight and high dose calcium carbonate control group, every treated animal 10.Sham operated rats is performed the operation: with 3% pentobarbital sodium intraperitoneal anesthesia, under strict aseptic technique, gets the other dorsal part two incision of lumbar vertebra and enters abdominal cavity, after extracing a little mesostenium, and carefully hemostasis layer-by-layer suture otch; Three dosage groups of model control group, the embodiment of the present invention one and the operation of high dose calcium carbonate control group, anesthesia is the same, under strict aseptic technique, get the other dorsal part two incision of lumbar vertebra, enter abdominal cavity dorsal part, after complete excision bilateral ovaries, carefully hemostasis layer-by-layer suture otch.Postoperative three days, sham operated rats and model control group were with distilled water gavage; The present invention's three dosage groups, i.e. 200mg/kgbw group, 400mg/kgbw group, 800mg/kgbw group (being equivalent to 5,10 and 20 times of human intaking amount 40mg/kg.bw group respectively), with the sample liquid gavage (preparation of gavage liquid: get 2g, 4g, 8g of the present invention respectively of preparation, adding distil water is settled to 100ml, is mixed with the sample liquid of 200mg/kgbw, 400mg/kgbw, 800mg/kgbw); High dose group calcium carbonate control group per os pours into the calcium carbonate of 224mg/kgbw, and this dosage is equivalent to high dose group level of the present invention.All animal gavage amounts are 10ml/kgbw, and once a day, continuous gavage 90 days, weighs weekly and adjust gavage amount by body weight.Test last femoral artery sacrificed by exsanguination animal, take out right side femur, with 105 DEG C of baking ovens, bake to constant weight, weigh bone weight.DPX-L Dual-energy X-rays absorptionmetry is adopted to measure fl bone density (g/cm
2), its concrete assay method scans whole fl with DPX-L Dual-energy X-rays absorptionmetry, represents this bone bone density with the mean bone density of bone.Adopt the right femur calcium content of atomic absorption spectroscopy determination.
Table 1 is on the impact of rat bone density and calcium content of bone
| Group | Number of animals | Fl bone density (g/cm2) | Right bone calcium content of femur (mg/g) |
| Sham operated rats | 10 | 0.2098±0.0232 | 178.02±9.23 |
| Model control group | 10 | 0.2161±0.0218 | 176.29±10.61 |
| High dose calcium carbonate control group | 10 | 0.2015±0.0274 | 132.05±11.07 |
| 200mg/kg.bw group | 10 | 0.2352±0.0156 | 182.41±3.11 |
| 400mg/kg.bw group | 10 | 0.2422±0.0134 | 186.15±10.96 |
| 800mg/kg.bw group | 10 | 0.2532±0.0171 | 187.36±11.36 |
From table 1, bone density, the calcium content of bone of the present invention's three dosage groups compare model control group, and there were significant differences, illustrate that the present invention has replenishing the calcium, increases the effect of bone density.
Detailed description of the invention
For making those skilled in the art understand production technology of the present invention and technique effect in detail, introduce application of the present invention and technique effect further with concrete production instance below.
Embodiment one: the preparation of granule
Take calcium carbonate 1500g, vitamin K
14g, vitamin K
34g, vitamin K
4then 4g and sucrose 2394g is the dissolve with ethanol vitamin K of 95% by 40ml concentration
1, vitamin K
3, vitamin K
4, then add the dilution of 350ml purified water, obtain wetting agent for subsequent use.After calcium carbonate and sucrose mix homogeneously, with gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, subpackage, obtain described granule.
Embodiment two: the preparation of granule
Take calcium carbonate 1200g, vitamin K
1then 10g and sucrose 2388g is the dissolve with ethanol vitamin K of 95% by 30ml concentration
1, then add the dilution of 250ml purified water, obtain wetting agent for subsequent use.By calcium carbonate and sucrose mix homogeneously, with gained wetting agent soft material, granulate, under the condition of 40 DEG C, carry out drying, granulate, subpackage, obtain described granule.
Embodiment three: the preparation of granule
Take calcium carbonate 2000g, vitamin K
1then 15g and sucrose 2694g is the dissolve with ethanol vitamin K of 95% by 35ml concentration
1, then add the dilution of 200ml purified water, obtain wetting agent for subsequent use.By calcium carbonate and sucrose mix homogeneously, with gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, subpackage, obtain described granule.
Embodiment four: the preparation of tablet
Take calcium carbonate 1000g, vitamin K
2then 20g, microcrystalline Cellulose 200g and carboxymethylstach sodium 20g are the dissolve with ethanol vitamin K of 95% by 35ml concentration
2, then add the dilution of 200ml purified water, obtain wetting agent for subsequent use.By calcium carbonate, microcrystalline Cellulose and carboxymethylstach sodium mix homogeneously, with gained wetting agent soft material, granulate, carry out drying, granulate under the condition of 50 DEG C, add magnesium stearate 2.5g mixing, tabletting, obtains described conventional tablet.
Embodiment five: the preparation of film coated tablet
Take calcium carbonate 2500g, vitamin K
3then 18g, microcrystalline Cellulose 200g and carboxymethylstach sodium 20g are the dissolve with ethanol vitamin K of 95% by 40ml concentration
3, then add the dilution of 180ml purified water, obtain wetting agent for subsequent use.By calcium carbonate, microcrystalline Cellulose and carboxymethylstach sodium mix homogeneously, with gained wetting agent soft material, granulate, drying is carried out under the condition of 60 DEG C, granulate, adds magnesium stearate 2.5g mixing, tabletting, take hypromellose 85g and Pulvis Talci 15g coating operations routinely again, obtain described film coated tablet.
Embodiment six: the preparation of chewable tablet
Take calcium carbonate 1200g, vitamin K
24g, vitamin K
34g, vitamin K
4then 4g, sucrose 300g are the dissolve with ethanol vitamin K of 95% by 40ml concentration
2, vitamin K
3, vitamin K
4, then add the dilution of 150ml purified water, obtain wetting agent for subsequent use.By calcium carbonate and sucrose mix homogeneously, with gained wetting agent soft material, granulate, under the condition of 60 DEG C, carry out drying, granulate, add micropowder silica gel 30g and mix, tabletting, obtains described chewable tablet.
Embodiment seven: the preparation of chewable tablet
Take calcium carbonate 2200g, vitamin K
14g, vitamin K
2then 4g, lactose 100g and mannitol 200g are the dissolve with ethanol vitamin K of 95% by 30ml concentration
1, vitamin K
1, then add the dilution of 200ml purified water, obtain wetting agent for subsequent use.By calcium carbonate, lactose and mannitol mix homogeneously, with gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, add micropowder silica gel 30g and mix, tabletting, obtains described chewable tablet.
Embodiment eight: the preparation of capsule
Take calcium carbonate 1600g, vitamin K
36g, vitamin K
4then 6g is the dissolve with ethanol vitamin K of 95% by 30ml concentration
3, vitamin K
4, then add the dilution of 200ml purified water, obtain wetting agent for subsequent use.By calcium carbonate gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, add magnesium stearate 3g mixing, use Capsules filling, obtain described capsule.
Claims (1)
1. a preparation method for calcium carbonate-vitamin K pharmaceutical preparation, is characterized in that, the method comprises the following steps: get calcium carbonate 1600g, vitamin K
36g, vitamin K
4then 6g is the dissolve with ethanol vitamin K of 95% by 30mL concentration
3, vitamin K
4, then add the dilution of 200mL purified water, obtain wetting agent for subsequent use; By calcium carbonate gained wetting agent soft material, granulate, under the condition of 50 DEG C, carry out drying, granulate, add magnesium stearate 3g mixing, use Capsules filling, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310076599.2A CN103142641B (en) | 2013-03-11 | 2013-03-11 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310076599.2A CN103142641B (en) | 2013-03-11 | 2013-03-11 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103142641A CN103142641A (en) | 2013-06-12 |
| CN103142641B true CN103142641B (en) | 2015-05-20 |
Family
ID=48541150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310076599.2A Active CN103142641B (en) | 2013-03-11 | 2013-03-11 | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103142641B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104432099B (en) * | 2014-12-22 | 2017-02-01 | 威海百合生物技术股份有限公司 | Health food containing vitamin K2 |
| CN104738623A (en) * | 2015-03-17 | 2015-07-01 | 徐州医学院 | Mushroom powder capsule rich in vitamin K2 and calcium agent and preparation method thereof |
| CN107960663A (en) * | 2017-11-24 | 2018-04-27 | 南通励成生物工程有限公司 | Carbonic acid calcium-nutrition intensifying agent and preparation method |
| CN114832020B (en) * | 2022-05-30 | 2023-03-17 | 北京朗迪制药有限公司 | Pharmaceutical composition for preventing and treating child developmental disorder and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1016895A6 (en) * | 2005-12-16 | 2007-09-04 | Psaltopoulos Emmanuel | Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3 |
| CN101828707A (en) * | 2009-03-10 | 2010-09-15 | 上海培宝康实业股份有限公司 | Nutrition composition and application thereof |
| CN101537050B (en) * | 2009-05-08 | 2011-06-01 | 无锡健特药业有限公司 | Health product capable of enhancing bone density and immune function, and preparation method and applications thereof |
-
2013
- 2013-03-11 CN CN201310076599.2A patent/CN103142641B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1016895A6 (en) * | 2005-12-16 | 2007-09-04 | Psaltopoulos Emmanuel | Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3 |
| CN101828707A (en) * | 2009-03-10 | 2010-09-15 | 上海培宝康实业股份有限公司 | Nutrition composition and application thereof |
| CN101537050B (en) * | 2009-05-08 | 2011-06-01 | 无锡健特药业有限公司 | Health product capable of enhancing bone density and immune function, and preparation method and applications thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103142641A (en) | 2013-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101537170B (en) | Compound for preventing osteoporosis and osteoarthrosis | |
| JP2010505818A (en) | Compositions containing crustacean gastrolith components and uses thereof | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| CN103142641B (en) | Calcium carbonate-vitamin K pharmaceutical preparation and preparation method thereof | |
| CN102085356B (en) | Composition for increasing bone mineral density and preparation method thereof | |
| CN112584848A (en) | Probiotic compositions and uses thereof | |
| CN104116022B (en) | Composite health food for improving women climacteric syndrome and preparation method thereof | |
| CN103721242A (en) | New application of pharmaceutical composition in prevention or treatment of osteoporosis | |
| CN104146260B (en) | A kind of health food increasing bone density and preparation method thereof | |
| CN105816469B (en) | Application of 20(R) -ginsenoside Rg3 in preparation of medicine or health product for treating osteoporosis and medicine | |
| CN104587016B (en) | A kind of Chinese traditional medicine navel patch and preparation method for treating constipation | |
| CN104127861B (en) | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof | |
| CN103142568B (en) | Calcium acetate-vitamin K pharmaceutical preparation and preparation method thereof | |
| CN104824677A (en) | Bone density increase health food and preparation method thereof | |
| CN103006693A (en) | Double-vitamin calcium carbonate composition | |
| CN105770850A (en) | Health care product for adjuvant treatment of osteoarticular diseases and preparation method of health care product | |
| CN103040844A (en) | Two-dimensional calcium acetate composition | |
| CN101167754A (en) | Application of sea bone peptide in preparing medicine, health-care food or food for preventing osteoporosis | |
| WO2018107324A1 (en) | Calcium supplement composition for decreasing risk of hypercalcemia and use thereof | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| WO2016124080A1 (en) | Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug | |
| CN101904958B (en) | Oral medicinal composition for treating fracture | |
| CN104544067B (en) | Health food composition for preventing osteoporosis and preparation method thereof | |
| CN103285203A (en) | Traditional Chinese medicine composition for preventing and treating bone fracture and preparation method thereof | |
| CN107929617B (en) | Traditional Chinese medicine composition and pill for treating bone and joint tuberculosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |